Parkinson's disease (PD) is the second most common neurodegenerative disease after
Alzheimer's disease. While PD is typically characterized by motor symptoms such as bradykinesia,
tremor, rigidity, postural instability, and gait disturbances, patients frequently present numerous
non-motor symptoms, including gastrointestinal manifestations. These gastrointestinal
symptoms may be fundamentally related to alpha-synuclein pathology, and dopaminergic
treatments may further contribute to reduced gastrointestinal motility. Gastrointestinal
symptoms can occur before the diagnosis of PD and at any stage during the disease
course, affecting the gastrointestinal tract from the oral cavity to the anus. If left untreated,
gastrointestinal problems can impair medication absorption, leading to motor fluctuations and
potentially causing complications such as malnutrition and aspiration pneumonia, which may
be life-threatening. Therefore, clinicians should not overlook gastrointestinal symptoms in PD
patients. Gastrointestinal symptoms in PD can manifest diversely throughout the entire disease
course, requiring healthcare providers to recognize these symptoms and provide individualized
management. Since current treatments for PD-related gastrointestinal symptoms are largely derived from data in non-PD patients, future research and clinical guideline development in this
f
ield are required for establishing evidence-based care protocols.